A presumed case of Darbepoetin-induced myocardial infarction in the patient with MDS-RARS
Oncology and Hematology
Clinical Case Reports
Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin-stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascular risk factors might be beneficial in preventing future cardiovascular mortality.
Zafar, Aneeqa Ahsan and Kouides, Peter, "A presumed case of Darbepoetin-induced myocardial infarction in the patient with MDS-RARS" (2020). Rochester Regional Health authored publications and proceedings. 134.